Moderna announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants. These results suggest that Moderna’s updated COVID-19 vaccine may effectively target the expected circulating variants of COVID-19 during the upcoming vaccination season. The World Health […]

Biogen has agreed to acquire Plano, Texas-based Reata Pharmaceuticals for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved Skyclarys (omaveloxolone) is the first and only approved treatment in the U.S. for the […]

Biogen and its collaboration partner Sage Therapeutics have announced that the FDA has approved Zurzuvae (zuranolone) for adults with postpartum depression (PPD). Zurzuvae is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. Zurzuvae is expected to launch and be commercially available in the […]

Pharma giant Regeneron Pharmaceuticals and clinical-stage biotech Decibel Therapeutics have announced a definitive agreement for the acquisition of Decibel by Regeneron. The proposed acquisition values Decibel at a total equity value of approximately $109 million based on the amount payable at closing, and a total equity value of up to approximately $213 million upon achievement […]

Following hot on the heels of FDA approval for the Biogen/Eisai Alzheimer’s drug Leqembi, Eli Lilly presented results from its Phase 3 study of donanemab which showed that the drug significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s. The data were shared at the 2023 Alzheimer’s Association International Conference as a featured […]

Cambridge-based Korro Bio and Lexington’s Frequency Therapeutics have agreed to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs under the name Korro Bio, Inc. and will apply to trade on Nasdaq. In addition, Korro Bio has secured commitments from a […]

Eli Lilly and Cambridge-based Sigilon Therapeutics have announced that Lilly will acquire Sigilon in a transaction worth up to $310 million. The transaction is expected to close in the third quarter of 2023, subject to customary closing conditions. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of […]

The FDA has granted full approval to Leqembi, the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease (AD). According to Eisai, which developed the drug with Biogen, Leqembi could generate $7 billion in annual sales globally by 2030. […]

Sarepta Therapeutics has announced FDA accelerated approval of its Elevidys gene therapy for the treatment of children aged 4 through 5 years with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the dystrophin gene. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Elevidys is intended to treat […]

Bluebird Bio has announced that the FDA has accepted the Biologics License Application (BLA) for lovo-cel for priority review. Lovo-cel is a one-time gene therapy for individuals living with sickle cell disease (SCD). It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables production of […]